drugset / Trial / NCT05661669
Ketamine for the Treatment for Alcohol Use Disorder in the ED
Phase 2
Withdrawn
Brigham and Women's Hospital
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The investigators' approach is to conduct a pilot double-blind, placebo-controlled randomized clinical trial with individuals with alcohol use disorder (AUD) seeking inpatient alcohol detoxification in the emergency department (ED) to receive either intravenous ketamine or saline placebo. The primary aim is to evaluate the intervention's safety. The secondary aim is to evaluate the preliminary efficacy of alcohol-related outcomes.
Timeline
- Start
- 2023-09-01
- Primary completion
- 2024-08-19
- Completion
- 2024-08-19
Outcome
Outcome not reported
Stopped: “After months of screening, we screened 175 individuals, only 3 were eligible, 2 declined, and 1 was moved to a different floor before study activities were able to take place.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.8 mg/kg | Intravenous |